Search for Clinical Trial Results
Lymphoma, T-Cell - 77 Studies Found
Status | Study |
Recruiting |
Study Name: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Condition:
|
Terminated |
Study Name: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Condition: T-cell Lymphoma Date: 2009-05-05 Interventions:
|
Not yet recruiting |
Study Name: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Condition: Peripheral T Cell Lymphoma Date: 2016-11-03 Interventions:
|
Recruiting |
Study Name: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study Condition: Peripheral T-cell Lymphomas Date: 2015-07-26 Interventions:
|
Recruiting |
Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condition: Cutaneous T Cell Lymphoma Date: 2010-05-25 Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
Study Name: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-09-09 Interventions:
|
Completed |
Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condition: Lymphoma, T-Cell, Cutaneous Date: 2011-11-29 Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
Study Name: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma Condition: Lymphoma, T-Cell, Cutaneous Date: 2002-08-08 Interventions:
|
Completed |
Study Name: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Condition: Lymphoma, T-Cell, Cutaneous Date: 2005-09-13 Interventions: Drug: ONTAK (denileukin difitox, DAB389IL-2) |
No longer available |
Study Name: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Condition: Lymphoma, T-Cell, Cutaneous Date: 2007-01-05 Interventions: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |